What is Shenzhen YHLO Biotech Co., Ltd.'s (688575.SS) StockRank?

MoatMap's StockRank for Shenzhen YHLO Biotech Co., Ltd. (688575.SS) is 26/100, with a Sell signal. This is a composite score combining Quality (54), Value (28), and Momentum (35) factor ranks across MoatMap's 20,000+ stock universe.

Does Shenzhen YHLO Biotech Co., Ltd. have an economic moat?

Shenzhen YHLO Biotech Co., Ltd. (688575.SS) has a Quality factor score of 54/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Shenzhen YHLO Biotech Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Shenzhen YHLO Biotech Co., Ltd. (688575.SS) is Sell, based on a StockRank of 26/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Shenzhen YHLO Biotech Co., Ltd. in?

Shenzhen YHLO Biotech Co., Ltd. (688575.SS) operates in the Healthcare sector, specifically the Medical Devices industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

688575.SS

SELLREMOVE

Shenzhen YHLO Biotech Co., Ltd. · Healthcare · China · $870M · Avg Vol: $10M/d

StockRank

P/E (TTM)

191.4x

ROE

2.8%

D/E

0.3x

Dividend %

0.2%

Director Trades · 180d

+$224.2K →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Shenzhen YHLO Biotech operates in the highly competitive Chinese in-vitro diagnostics market, which is subject to centralized government procurement price cuts that destroy long-term ROIC.

COMPANY DESCRIPTION

Shenzhen YHLO Biotech Co., Ltd. is a global developer of in vitro diagnostic (IVD) instruments and reagents, with a core focus on chemiluminescence immunoassay (CLIA) technology. The company is a market leader in China's autoimmune disease diagnostic niche, offering a comprehensive menu of proprietary test assays. Its competitive moat is sustained by its closed-loop system design, where proprietary reagents must be run on its installed base of diagnostic instruments.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	588M	303M	297M	268M	-23.1%
EPS	0.26	0.09	0.08	0.01	-71.8%
Shares	567M	568M	570M	571M	+0.8%
Debt	70M	82M	134M	132M	23.7%
Equity	357M	378M	407M	399M	3.7%
Op CF	234M	-11M	78M	62M	-35.7%
Inv CF	-129M	-94M	-111M	-49M	—
Fin CF	2M	-3M	27M	-22M	—

PRICE (1M)-30.2%

SMA 50SMA 200

$1.37

RSI (14)

27.9

52W High

$2.51

From 52W High

0.5%

SCORE BREAKDOWN

Quality

ROIC

3.5%52.4

ROE

2.8%50.1

GP/Assets

26.9%60.2

Op. Margin

10.9%68.1

FCF/Assets

-1.3%45.8

Piotroski

—83.4

Int. Cover

5.1x55.2

D/E Ratio

0.35x40.0

Current Ratio

2.19x41.1

Value

P/E (TTM)

191.4x4.8

EV/EBITDA

12.0x36.2

P/FCF

—N/A

P/B

2.0x54.9

P/S

3.1x56.1

Div Yield

0.2%6.4

Momentum

52W High %

55%29.9

RS 6M

-45%26.2

SMA 50/200

0.87x25.4

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

77%82.7

FUNDAMENTALS

Market Cap

$870M

P/E (Forward)

—

Gross Margin

64.2%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 688575.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
688575.SS	Shenzhen YHLO Biotech Co., Ltd.(you)	$870M	26	SELL
301370.SZ	GKHT Medical Technology Co., Ltd.	$629M	24	SELL
1609.HK	Star Sports Medicine Co., Ltd.	$1.4B	26	SELL
300633.SZ	SonoScape Medical Corp.	$1.3B	28	SELL
300869.SZ	Contec Medical Systems Co.,Ltd	$681M	21	SELL
688085.SS	Shanghai Sanyou Medical Co., Ltd	$755M	17	STRONG SELL
688626.SS	Xiangyu Medical Co.,Ltd	$1.2B	20	SELL
301602.SZ	Shantou Institute of Ultrasonic Instrument Co., Ltd.	$1.0B	15	STRONG SELL
688212.SS	Shanghai Aohua Photoelectricity Endoscope Co., Ltd.	$603M	16	STRONG SELL
9877.HK	Jenscare Scientific Co., Ltd.	$434M	29	SELL

Peer medians: ROE 4.8% · P/E 27.6x · Gross margin 53.0%

Shenzhen YHLO Biotech Co., Ltd. (688575.SS) — Stock Score Summary

Shenzhen YHLO Biotech Co., Ltd. (688575.SS) has a MoatMap StockRank of 26/100 based on Quality (54/100), Value (28/100), and Momentum (35/100) factor scores. The current signal is SELL. Shenzhen YHLO Biotech operates in the highly competitive Chinese in-vitro diagnostics market, which is subject to centralized government procurement price cuts that destroy long-term ROIC.

Key Financial Metrics

Price	$1.37
Market Cap	$870M
P/E (TTM)	191.40
Price/Book	2.02
Return on Equity	2.8%
Return on Invested Capital	3.5%
Debt/Equity	34.75
Gross Margin	64.2%
Operating Margin	10.9%
Revenue Growth	-4.8%
Dividend Yield	0.2%
Free Cash Flow	$-1M

Shenzhen YHLO Biotech Co., Ltd. operates in the Medical Devices industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Shenzhen YHLO Biotech Co., Ltd.’s (688575.SS) StockRank?: MoatMap’s StockRank for Shenzhen YHLO Biotech Co., Ltd. (688575.SS) is 26/100, with a Sell signal. It is a composite of Quality (54), Value (28), and Momentum (35) factor ranks across MoatMap’s 20,000+ stock universe.
Does Shenzhen YHLO Biotech Co., Ltd. have an economic moat?: Shenzhen YHLO Biotech Co., Ltd. (688575.SS) has a Quality factor score of 54/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Shenzhen YHLO Biotech Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Shenzhen YHLO Biotech Co., Ltd. (688575.SS) is Sell, based on a StockRank of 26/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Shenzhen YHLO Biotech Co., Ltd. in?: Shenzhen YHLO Biotech Co., Ltd. (688575.SS) operates in the Healthcare sector, specifically the Medical Devices industry (China).